Liminatus Pharma, Inc. Class A Common Stock (NASDAQ:LIMN) — Stock Price
Liminatus Pharma, Inc. Class A Common Stock (NASDAQ:LIMN) is currently trading at $0.12 USD, up 13.59% today. Over the past 52 weeks, shares have ranged between $0.10 and $4.40. This page tracks Liminatus Pharma, Inc. Class A Common Stock's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see LIMN market cap.
Liminatus Pharma, Inc. Class A Common Stock (LIMN) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Liminatus Pharma, Inc. Class A Common Stock's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Liminatus Pharma, Inc. Class A Common Stock Income Statement — Revenue, Profit & Earnings by Year
Liminatus Pharma, Inc. Class A Common Stock's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Research & Development | $0.00 | $2.69 Million | $3.76 Million | $1.85 Million |
| SG&A | $2.97 Million | $645.00K | $1.06 Million | $856.00K |
| Total Operating Expenses | $2.97 Million | $2.91 Million | $2.59 Million | $2.71 Million |
| Operating Income | $-2.97 Million | $-2.91 Million | $-2.59 Million | $-2.71 Million |
| EBITDA | $-9.99 Million | $-2.75 Million | $-1.09 Million | $-2.71 Million |
| EBIT | $-9.99 Million | — | — | — |
| Interest Expense | $215.90K | $138.10K | $175.00K | $219.00K |
| Income Before Tax | $-10.21 Million | $-2.89 Million | $-1.19 Million | $-2.93 Million |
| Income Tax Expense | — | $18.84K | $33.99K | $539.82K |
| Net Income | $-10.21 Million | $-2.90 Million | $-1.23 Million | $-2.93 Million |
Liminatus Pharma, Inc. Class A Common Stock Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Liminatus Pharma, Inc. Class A Common Stock's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $512.79K | $2.83 Million | $4.50 Million | $15.49 Million | $276.44 Million |
| Total Current Assets | $500.57K | $812.66K | $210.88K | $360.65K | $421.92K |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | — | $6.46K | $945.00K | $100.00K | $1.26K |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $10.33 Million | $18.70 Million | $15.19 Million | $14.19 Million | $21.57 Million |
| Total Current Liabilities | $10.30 Million | $8.68 Million | $5.16 Million | $3.59 Million | $1.38 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | $1.10 Million | $4.32 Million | $15.62 Million | $11.45 Million | $-246.23K |
| Total Stockholder Equity | $-9.81 Million | $-15.87 Million | $-10.69 Million | $1.29 Million | $254.87 Million |
| Retained Earnings | $-38.87 Million | $-17.52 Million | $-14.88 Million | $-13.97 Million | $-21.13 Million |
Liminatus Pharma, Inc. Class A Common Stock Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Liminatus Pharma, Inc. Class A Common Stock generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-9.96 Million | $-3.11 Million | $-3.35 Million | $-869.00K | $-1.22 Million |
| Capital Expenditures | $13.11K | $0.00 | $0.00 | $0.00 | $0.00 |
| Free Cash Flow | $-9.98 Million | $-3.11 Million | $-3.35 Million | $-869.00K | $-1.22 Million |
| Investing Cash Flow | $-788.11K | $1.97 Million | $-819.00K | $263.96 Million | $-276.00 Million |
| Financing Cash Flow | $11.03 Million | $1.05 Million | $-450.00K | $5.92 Million | $277.55 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | $1.83K | $0.00 | — | — | — |
| Change in Cash | $281.34K | $648.11K | $-4.61 Million | $5.05 Million | $336.23K |
Liminatus Pharma, Inc. Class A Common Stock Earnings History — EPS Actual vs. Analyst Estimates
Track Liminatus Pharma, Inc. Class A Common Stock's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Dec 31, 2025 | -0.30 | — | — |
| Oct 06, 2025 | -0.07 | 0.00 | — |
| Jun 30, 2025 | 0.00 | — | — |
| Apr 16, 2025 | -0.12 | — | — |
| Dec 31, 2024 | -0.12 | — | — |
| Sep 30, 2024 | -0.09 | — | — |
| Jun 30, 2024 | -0.07 | — | — |
| Mar 31, 2024 | -0.12 | — | — |